OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

Summary by AI BETAClose X

OKYO Pharma announced that Gary Jacob, Chief Development Officer and Director, purchased 30,980 ordinary shares on NASDAQ at $1.59 per share, increasing his total stake to 108,920 shares. This insider buying activity occurs as the company advances its investigational therapy Urcosimod for neuropathic corneal pain, having recently reported positive Phase 2a data and planning to initiate a Phase 2b/3 study in the first half of the year.

Disclaimer*

UK 100

Latest directors dealings